Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.74 EUR 1.86% Market Closed
Market Cap: 127.7m EUR

EV/EBITDA
Enterprise Value to EBITDA

-5.8
Current
-6.4
Median
4.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-5.8
=
Enterprise Value
112.4m EUR
/
EBITDA
-19.5m EUR
EBITDA Growth EV/EBITDA to Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average EV/EBITDA: 16.3
Negative Multiple: -5.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 018.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.2
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.1
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.3
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -275.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-5.5
2-Years Forward
EV/EBITDA
-3.2
3-Years Forward
EV/EBITDA
-5